Technology Transfer OfficeView Profile
Yissum - Research Development Company of the Hebrew University posted this:Early Detection and Personalized Treatment of Breast Cancer, Using Comparative GenomicsUsing cutting-edge comparative genomics, data integration, and machine learning, the researchers will develop a comprehensive gene panel that can identify increased risk of breast cancer and offer personalized treatment options based on PARP inhibitors. Project ID : 6-2018-6690
Laijo Jose posted this:
Manager-Tech Transfer at Centre For Future (CFF)
Russell Nicholls posted this:
Licensing Manager at Curtin University
Small and Medium Enterprise
Hygea Salud y Nutrición posted this:Nutritional software which makes automatically personalized diets.Vitadieta is a system of Medical Nutrition Therapy, which makes automatically personalized diets for a wide range of goals (lose weight, healthy diet, sports nutrition, pathologies...). The system could be integrate inside a third-party software, or works online. Vitadieta offers functionalities of cross-selling oriented to franchises, recomending product and services of each franchise with the diets.
Agro Biotech International Exports Pvt. Lt. posted this:White turmeric (Curcuma aromatica Salisb) is a multi face herbalWhite Turmeric (Curcuma aromatica Salisb) is a multi faced herbal used in the Cosmetic industries to cancer research institutes. We have the sufficiant raw materials for export. It is used for anti fertility usage. The practice of traditional medicine for the control of fertility in most parts of India is based on the uses of plant medicines for many years. Anti-inflammatory and wound healing activity of topical application of Curcuma aromatica Salisb.
Universidad de Alcalá-OTRI posted this:Double port injector to corneal transplant DMEKThe Reseacrh group in Cell biology of solid tumors and tisular regeneration from Alcala University and the Research group in Cellular Engineering from University from Hospital La Paz, have developed a new injector designed to reduce endotellial damage during the corneal endothelial graft implantation in eye´s anterior chamber. The group is looking for cooperation or commercial agreement with companies manufacturers of sanitary products and medical devices, ophthalmological clinics and hospitals.
Research & Technology Organization
UNIVERSIDAD DE ALICANTE posted this:A decision support system for melanoma diagnosis.A Spanish Research Group has developed a system to help in the recognition of a melanoma through the visual characteristics of an image of the skin lesion. This system can be used as an automated way to decide the urgency to refer a patient to the dermatologist.
Fundació URV posted this:A robust breast cancer computer-aided diagnosis systemWe analyze breast cancer in mammographies, ultrasonographies, magnetic resonance imaging (MRI) and thermographies. Our analysis includes mass/normal breast tissue classification, benign/malignant tumor classification in mammograms and ultrasound images, tumor detection in thermograms, mammogram registration and analysis of the evolution of breast tumors. We also quantify and visualize the evolution of breast tumors in patients undergoing medical treatment. While the previous works mainly focus on analyzing one type of breast images, we implement a robust CAD system for detecting, classifying and studying the evolution of breast cancer. This CAD system analyzes breast cancer in several types of medical images. To implement our CAD system, we use computer vision, pattern recognition and machine learning methods. We also need to collect a large scale breast cancer dataset from hospitals. This dataset should include mammograms, ultrasound, thermograms and MRI images for the same patients. Our CAD gives accurate diagnosis results because it gathers information from different sources.
IMIM Institut Recerca Hospital del Mar posted this:A TREATMENT FOR TRIPLE NEGATIVE BREAST CANCERTriple negative breast cancers are tipically associated with por prognosis, due to aggressive tumor phenotype(s), only partial response to chemoterapy and present lack of clinically established targeted therapies and respresent the focus of increasing interest at the clinical, biological and epidemiological level, as disclosed in Podo et al., Triple –negative breast cancer: Present challenges and new perspectives, Mol. Oncol., 2010, 4, 209-229. There is, thus, a particular need for new active agents suitable for breast cancer treatment, and in particular need for triple negative breast cancers.
JPT Peptide Technologies posted this:Custom Peptide SynthesisJPT Peptide Technologies has a substantial, long-standing expertise in custom peptide synthesis services, providing custom peptides with highest quality for even complex or unusual peptide sequences. If you would like to order a quality peptide synthesis service using regulated processes, choose JPT! Furthermore, our peptide synthesis service has a very high success rate (over 99%) as JPT has developed the know-how to choose and optimize the appropriate synthesis method for each peptide. We go the extra mile to get your peptides done!
DIT Hothouse posted this:U-Learn: A Training Model for Breast Ultrasound imagingU-learn is a training and learning model for radiographers and registrars for training in breast ultrasound imaging. The model assesses the performance of a trainee registrar before, during, and after training using the ultrasound imaging phantom which is a realistic representation of the breast.
DIT Hothouse posted this:Cervassist: Cervical Cancer AnalyserCurrently, cytologists are needed to examine smear samples under a microscope to visually assess the shape, size and stain pattern and determine if abnormal cells are present which could indicate cervical cancer. Alternatively, automated image analysis is used to determine nuclear density but cytologists are still needed to determine the presence of abnormal cells. The current processes are prone to human error and misdiagnosis can be up to 60%. They are also time consuming and costly.Sample user interface for spectral acquisition and classification. Researchers at DIT have invented an easy to use, low cost, automated analyser that uses a pre-defined library of known cell signatures and a proprietary classification algorithm to detect abnormal cells with an accuracy of 99%. The analyser can be used with a regular microscope, an image analyser or as a point-of-care system with results displayed using an intuitive user interface. The image and the classification can be saved in digital format, stored in a national database, and sent to the medical team or experts worldwide
Universidad de Alcalá-OTRI posted this:Anticancer activity of Ru (II) Arene complexes with oxime ligands.Spanish research group from the department of Inorganic Chemistry the University of Alcala, together with a Moroccan research group from the University of Abdelmalek Essaadi, have developed a process to synthesize metal complexes with anticancer properties, which can be used for cancer treatment and prevention. The group is looking for companies working in the pharmaceutical and biomedical sector to achieve license, collaborative or commercial agreements with technical assistance.
IMIM Institut Recerca Hospital del Mar posted this:A prognostic and predictive serum biomarker in Small Cell Lung CancerPeripheral blood and its components (serum, plasma, and circulating cells) is an easily accessible fluid. An ELISA-based system that exploit circulating protein biomarkers found in this medium is more convenient to the patient compared to a more invasive lung biopsy. The researchers have found that high levels of serum hepatocyte growth factor (sHGF) protein in patients with SCLC shows clearly predicted for shortened survival and an incremental risk for death. HGF is a natural ligand for the oncogenic epithelial transition factor (c-Met) transmembrane tyrosine kinase receptor and serum HGF could be predictive of individual responses to new anti-cancer drugs: the Met inhibitors. The Met inhibitors are targeted therapies against c-Met receptor that are currently in development for the treatment of other neoplasms and are planned to be evaluated in SCLC. Therefore, a biomarker of prediction of response to these new Met inhibitors would be crucial for correct selection of patients for the clinical trials. Incorrect selection through other biomarkers in NSCLC has leaded to lack of benefit from these drugs in already performed phase 3 clinical trials, stressing the relevance of correct patient selection